Origin invests in Desktop Genetics

Origin Capital has joined a syndicate of other investors to provide growth funding to Desktop Genetics, a developer of software used in genome-editing experiments. Tim de Vere Green, Origin’s CEO, commented: “We are delighted to have supported DTG. Although founded relatively recently, the business is a leader in this rapidly-growing field, and has already built commercial relationships with a number of important industry players.”

Desktop Genetics creates software that accelerates research and drives progress. Our DESKGEN platform enables the design, curation, and execution of genome editing experiments tailored to specific genotype of a target cell line. We’re on a mission to give every life scientist the power to design any genome editing experiment in any cell line–all from their desktop.

Find out more at: www.deskgen.com